# Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

> **NCT06652165** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 66 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** zanubrutinib combined with BEAM
- **DRUG:** BEAM

## Key facts

- **NCT ID:** NCT06652165
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652165, "Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06652165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*